HGHakan Gurdal

Hakan Gurdal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hakan Gurdal has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Dual-antigen AdV5 vaccines against Crimean-Congo hemorrhagic fever virus induce superior humoral and Th1-biased cellular immunity

    by Alireza Hanifehnezhad, Sidika Oztop, Ece Tavukcuoglu, Yigit Tanyeri, Ekimcan Yoyler, Gokcen Gokce Tepeli, Nilay Unal, Asuman Bozkir, M. Taner Karaoglu, Gunes Esendagli, et al.

    Platforms based on adenoviral vectors have proven their efficiency in developing vaccines and therefore can be considered potential candidates for immunization strategies against CCHFV. In this study, four replication-deficient recombinant human adenovirus serotype 5 (AdV5) vectors were engineered to express CCHFV antigens: a dual-antigen NP-P2A-Gc construct and monocistronic constructs for nucleoprotein (NP), glycoprotein complex precursor (GPC), and mature glycoprotein (Gc). Following GMP-compatible production and purification, vaccine candidates were evaluated in BALB/c mice (n = 4 per group) for immunogenicity and in IFNAR−/− mice (n = 4 per group) for protective efficacy using antigenically homologous or heterologous prime-boost regimens. Animals received priming immunization on day 0 and booster on day 28 followed by lethal CCHFV challenge (1000 TCID50) on day 42. Immune responses were characterized via ELISA, virus neutralization tests, cytokine profiling, ELISpot, and flow cytometry. Post-challenge survival, viral loads in target organs, and safety profiles were assessed. All AdV5 constructs successfully expressed the target antigens and induced rapid seroconversion, with 75–100% of animals exhibiting antibody responses after priming with a single dose. The dual-antigen formulations elicited the strongest Th1-polarized responses particularly nucleoprotein + Gc combinations with interferon-γ production more than 30-fold above baseline and preferential expansion of CD4+ T helper cells (60–70% of CD3+ populations). Neutralizing antibody titers varied across groups (80–160 arbitrary units in high responders) but did not directly correlate with survival outcomes. After lethal challenge, multiple vaccine formulations achieved 100% survival throughout the 10-day observation period, while only control groups showed no protection. All vaccinated animals demonstrated significant viral load reduction of two to four logs in liver and spleen tissues, with some achieving complete clearance of the virus. Furthermore, no off-target vector dissemination was detected in examined tissues confirming safety profile of the constructs. Immunization with adenovirus serotype 5 (AdV5) vectors expressing CCHFV antigens elicited potent humoral and cellular immune responses, conferring 100% protection against lethal viral challenge across the majority of evaluated formulations. Sterilizing immunity was observed in some animals, along with evidence that protection operates through multiple immune mechanisms including both neutralizing and non-neutralizing antibody-mediated pathways. These results strongly support further clinical development of AdV5-based CCHFV vaccines, with multiple formulation strategies showing high efficacy and providing flexibility for clinical advancement. GMP-compatible production methods have been successfully implemented for these candidates, supporting their advancement toward non-human primate studies and Phase I clinical trials.

  • miR-770-5p regulates KDM5B and links its nuclear localization to HER2 signaling in trastuzumab-resistant breast cancer

    by Senem Noyan, Hakan Gurdal, Alp Can, Bala Gur Dedeoglu

    Therapeutic resistance to trastuzumab remains a critical limitation in the management of HER2-positive (HER2+) breast cancer. Emerging evidence implicates epigenetic regulators, including microRNAs and histone demethylases, in modulating HER2 signaling and drug responsiveness. This study aimed to investigate the mechanistic role of miR-770-5p and its interplay with KDM5B in the context of trastuzumab resistance. An integrative approach combining in silico analyses with in vitro functional assays was employed in trastuzumab-sensitive and -resistant HER2 + breast cancer cell lines. Molecular, subcellular, and phenotypic effects of miR-770-5p modulation were assessed using qRT-PCR, Western blotting, immunofluorescence, RNA-FISH, luciferase reporter assays, and live-cell imaging. KDM5B was significantly overexpressed in HER2 + tumors and inversely correlated with HER2 expression. miR-770-5p directly targeted KDM5B and was associated with coordinated regulation of HER2 signaling at both transcription-associated and post-transcriptional levels. Overexpression of miR-770-5p was associated with reduced expression of KDM5B, TCF12, and GRB7, supporting the involvement of a KDM5B–TCF12–GRB7 regulatory network in HER2 modulation. Functionally, miR-770-5p reversed EMT-associated phenotypic features and enhanced trastuzumab sensitivity. Clinically, reduced KDM5B expression was associated with improved distant metastasis-free survival in ER+/HER2-high breast cancer patients. Collectively, miR-770-5p functions as a nuclear-associated regulatory microRNA that modulates HER2 signaling through epigenetic regulation of KDM5B and associated downstream networks. These findings suggest a previously unrecognized regulatory mechanism contributing to trastuzumab response and provide potential therapeutic avenues for HER2-positive breast cancer.

  • Open Access

    miR-216b-5p promotes late apoptosis/necroptosis in trastuzumab-resistant SK-BR-3 cells

    by İşTar Burcu Dolapçi, Senem Noyan, Ayşegül Yücel Polat, Hakan Gürdal, Bala Gür Dedeoğlu

    Breast cancer is the most common cancer in women. The human epidermal growth factor receptor 2 (HER2) overexpressing subtype is related to poor prognosis with an aggressive phenotype and is reported as one of the most commonly seen subtypes. Trastuzumab is prevalently used as a treatment method for HER2+ breast cancer however, resistance to the drug frequently occurs following the treatment. MicroRNAs (miRNAs) are 19-23 nucleotide long small RNAs, which regulate gene expression at posttranscriptional level and studies show that there are differentially expressed miRNAs between drug sensitive and resistant groups, indicating that they might have some key roles in drug effectiveness. In this study, the aim is to find out the role of miR-216b-5p in trastuzumab resistance. SK-BR-3 cells developed resistance to trastuzumab after continuous treatment with increasing concentrations of the drug for 6 months. To investigate the effect of miR-216b-5p on cancer cell behavior in resistance state, proliferation, motility, and invasion capacities of these resistant cells were analyzed by xCELLigence real-time cell analyzer. To further understand the molecular mechanisms underlying the regulation of resistant SK-BR-3 cells by miR-216b-5p, microarray analysis was performed. Apoptosis analysis was also performed since the pathway enrichment analysis pointed out cell death related pathways. Th e proliferation, motility, and invasion capacities of the miR-216b-5p transfected resistant cells were diminished compared to sensitive cells. We identified the necroptosis signaling pathway as the result of microarray and pathway enrichment analyses. STAT1, IRF9, and PKR were validated as the significant elements of the pathway, which are also the putative targets of miR-216b-5p. Our apoptosis analysis showed that a significant amount of trastuzumab resistant SK-BR-3 cells entered to late apoptosis/necrosis stage upon miR- 216b-5p overexpression, it could be concluded that reexpression of miR-216b-5p sensitizes trastuzumab resistance through necroptosis in breast cancer.


  • Open Access

    Overexpression of β-Arrestins inhibits proliferation and motility in triple negative breast cancer cells

    by Saber Yari Bostanabad, Senem Noyan, Bala Gur Dedeoglu, Hakan Gurdal

    β-Arrestins (βArrs) are intracellular signal regulating proteins. Their expression level varies in some cancers and they have a significant impact on cancer cell function. In general,the significance of βArrs in cancer research comes from studies examining GPCR signalling. Given the diversity of different GPCR signals in cancer cell regulation, contradictory results are inevitable regarding the role of βArrs. Our approach examines the direct influence of βArrs on cellular function and gene expression profiles by changing their expression levels in breast cancer cells, MDA-MB-231 and MDA-MB-468. Reducing expression of βArr1 or βArr2 tended to increase cell proliferation and invasion whereas increasing their expression levels inhibited them. The overexpression of βArrs caused cell cycle S-phase arrest and differential expression of cell cycle genes,CDC45, BUB1, CCNB1, CCNB2, CDKN2Cand reduced HER3, IGF-1R, and Snail. Regarding to the clinical relevance of our results, low expression levels of βArr1 were inversely correlated with CDC45, BUB1, CCNB1, and CCNB2 genes compared to normal tissue samples while positively correlated with poorer prognosis in breast tumours. These results indicate that βArr1 and βArr2 are significantly involved in cell cycle and anticancer signalling pathways through their influence on cell cycle genes and HER3, IGF-1R, and Snail in TNBC cells.


  • Assessment of replication of bovine herpesvirus type 4 in human glioblastoma and breast cancer cells as a potential oncolytic virus

    by Touraj Aligholipour Farzani, Seval Bilge Dagalp, Aykut Ozkul, Hakan Gurdal, Firat Dogan, Feray Alkan

    Oncolytic viruses have been extensively used in cancer treatment due to their tropism, selective replication only in tumor cells, and possible synergic interaction with other therapeutics. Different researchers have demonstrated that bovine herpesvirus 4 (BoHV-4), a member of the gammaherpesviridae family, has oncolytic potential in some human-origin cancer cell lines like glioma through the selective replication strategy. Using four apoptosis detection methods, namely MTT, LDH, TUNEL, and Annexin V assays, we evaluated the apoptotic effect of BoHV-4 Movar33/63 reference strain along with a recombinant BoHV-4 expressing EGFP in U87 MG cells (human glioblastoma cell line), MDA MB-231 (human breast cancer cell line), and MCF10a (non-tumorigenic human mammary epithelial cell line). Our findings indicate that this virus can replicate and induce apoptosis in these cell lines and hinder in vitro proliferation in a dose-dependent manner. In conclusion, BoHV-4 has in vitro potential as a novel oncolytic virus in human cancer therapy. However, its replication potential in the MCF10a cells as a non-tumorigenic human mammary epithelial cell line is a concern in using this virus in cancer therapy, at least against human mammary tumors. Further studies must therefore be conducted to examine the specific apoptotic pathways induced by this virus to move on to further experiments.


  • Open Access

    Immunological Analysis of a CCHFV mRNA Vaccine Candidate in Mouse Models

    by Touraj Aligholipour Farzani, Katalin Földes, Koray Ergünay, Hakan Gurdal, Aliye Bastug, Aykut Ozkul

    Development of new vaccine platforms against viral diseases is considered urgent. In recent years, mRNA constructs have attracted great interest in this field due to unique advantages over conventional gene transfer platforms. In the present study, we developed a new naked conventional mRNA vaccine expressing the non-optimized small (S) segment of the Ank-2 strain of Crimean-Congo Hemorrhagic Fever virus (CCHFV). We then analyzed its single and booster dose immunogenicity and protection potential in the challenge assay in two mice models, including IFNα/β/γR−/− and C57BL/6. The results obtained from the immunological assays, namely IL-4 and IFN-gamma ELISPOT, intracellular IFN-gamma staining, in-house sandwich ELISA, and survival data, demonstrated that our construct elicited the production of anti-nucleocapsid (N) specific immune responses in both mice models. A 100% protection rate was only obtained in the booster dose group of IFNα/β/γR−/− mice, indicating that this platform needs further optimization in future studies. In conclusion, we assessed a novel approach in CCHFV vaccination by introducing a conventional mRNA platform which can be considered in future experiments as an efficient and safe way to battle this disease.


  • Open Access

    Class III β-tubulin Expression in Colorectal Neoplasms Is a Potential Predictive Biomarker for Paclitaxel Response

    by Sidika Öztop, Aynur Işik, Güneş Güner, Hakan Gürdal, Erdem Karabulut, Erkan Yilmaz, Ayteki̇n Akyol

    Background/Aim: The challenges of cololorectal cancer (CRC) management include prediction of outcome and drug response or chemoresistance. This study aimed at examining whether βIII-tubulin (TUBB3), present in various types of normal tissues and cancer, is a biomarker for the response of colorectal neoplasms to paclitaxel. Materials and Methods: Six tissue microarrays (TMAs) including 14 colon mucosa, 78 polyps and 202 CRCs were constructed. Assessment of TUBB3 expression was performed by immunohistochemistry, and it was scored as negative, focal and positive. In the HCT116 cell line, TUBB3 expression was silenced with siRNA. Paclitaxel toxicity was evaluated in TUBB3-silenced and control HCT116 cell lines. Results: The non-neoplastic colon mucosa was negative for TUBB3, while some of colon adenomas and CRCs expressed TUBB3 in various levels from focal to diffuse. TUBB3-expressing CRCs tended to have poor prognosis and silencing of TUBB3 sensitized the cells to paclitaxel. Conclusion: TUBB3 was expressed in a subgroup of colorectal neoplasms. Suppression of TUBB3 potentialy sensitizes neoplastic cells to taxanes.


  • Partial agonistic effect of cetuximab on epidermal growth factor receptor and Src kinase activation in triple‑negative breast cancer cell lines

    by Hakan Gurdal, Matilda Merve Tuglu, Saber Yari Bostanabad, Başak Dalkiliç

    Cetuximab is a monoclonal antibody developed to inhibit the binding of growth factors and the subsequent activation of epidermal growth factor receptor (EGFR). Triple‑negative breast cancer (TNBC) is resistant to cetuximab treatment. The aim of the present study was to examine the partial agonistic properties of cetuximab, which not only blocks ligand binding, but also partially triggers EGFR activation, which may lead to cetuximab resistance in TNBC. The phosphorylation of growth factor receptors and their signalling pathways were evaluated by determining the phosphorylation of EGFR, insulin‑like growth factor receptor (IGF‑1R), vascular endothelial growth factor receptor (VEGFR)‑2, Src kinase, phosphoinositide‑3‑kinase (PI3K), extracellular signal‑regulated kinase (ERK1/2) and serine/threonine‑specific protein kinase (Akt) and the degradation of EGFR, and by assessing the morphology and proliferation of MDA‑MB‑231 and MDA‑MB‑468 cells. Cetuximab treatment led to the phosphorylation of EGFR, VEGFR‑2, IGF‑1R and downstream signalling molecules, Src kinase and PI3K in these cells, as well as Akt in the MDA‑MB‑231 cells. The cetuximab‑mediated phosphorylation of IGF‑1R, VEGFR‑2 and Akt was inhibited by the EGFR kinase inhibitor, AG1478, and the Src kinase inhibitor, PP2. Cetuximab treatment led to the degradation of EGFR. The cetuximab‑induced phosphorylation and EGFR degradation were less prominent compared with those induced by EGF. Cetuximab partially inhibited EGF‑mediated responses. Cetuximab, similar with EGF, altered cellular morphology in a serum‑free medium. In both cell lines, the Src kinase inhibitor enhanced the cetuximab‑induced anti‑proliferative response. These results indicate that cetuximab exerts a partial agonistic effect on EGFR, which activates Src kinase and subsequently transactivates IGF‑1R and VEGFR‑2. This partial agonistic property is likely one of the mechanisms underlying the resistance of TNBC to cetuximab.


  • The role of dual‑specificity phosphatase 1 and protein phosphatase�1 in β2‑adrenergic receptor‑mediated inhibition of extracellular signal regulated kinase 1/2 in triple negative breast cancer cell lines

    by Matilda Merve Tuglu, Saber Yari Bostanabad, Gozde Ozyon, Başak Dalkili�, Hakan Gurdal

    Triple negative breast cancer cell lines express high levels of (2)-adrenergic receptor, which have a significant influence on the activity of extracellular signal-regulated kinase (ERK)1/2. Therefore, it is important to understand the link between (2)-adrenergic receptor signaling and ERK1/2 activity in terms of cancer cell regulation and cancer progression. Although the molecular mechanisms are not completely clarified, (2)-adrenergic receptor stimulation appears to reduce the basal levels of phosphorylated (p)ERK1/2 in MDA-MB-231 breast cancer cells. The aim of the current study was to determine the mechanism of (2)-adrenergic receptor-mediated ERK1/2 dephosphorylation by investigating the role of dual-specificity phosphatase (DUSP)1/6 and protein phosphatase (PP)1/2, which are established regulators of ERK1/2 phosphorylation, in MDA-MB-231 and MDA-MB-468 breast cancer cell lines. (E)-2-benzylidene-3-(cyclohexyl amino)-2,3-dihydro-1H-inden-1-one (BCI) and calyculin A were employed as DUSP1/6 and PP1/PP2 inhibitors, respectively. Subsequently, the protein levels of DUSP1, PP1, pPP1, ERK1/2 and pERK1/2 were measured by western blot analysis. Cells were transfected with DUSP1 small interfering (si)RNA or PP1 siRNA to inhibit their expression. The results demonstrated that (2)-adrenergic receptor agonists led to the dephosphorylation of basal pERK1/2 in MDA-MB-231 and MDA-MB-468 cells. The DUSP1/6 inhibitor, BCI, and the PP1/PP2 inhibitor, calyculin A, antagonized the (2)-adrenergic receptor-mediated dephosphorylation of ERK1/2. Furthermore, (2)-adrenergic receptor stimulation increased the protein expression level of DUSP1, with no effects on DUSP6, PP1 and PP2 expression, and enhanced the expression of the active form of PP1. Downregulation of the expression of DUSP1 or PP1 led to a decline in the (2)-adrenergic receptor-mediated dephosphorylation of ERK1/2. The results of the present study indicate that (2)-adrenergic receptor-mediated dephosphorylation of ERK1/2 may be associated with the activity of DUSP1 and PP1 in MDA-MB-231 and MDA-MB-468 triple negative breast cancer cell lines. The clinical importance of (2)-adrenergic receptor-mediated inactivation of ERK1/2 as well as the activation of DUSP1 and PP1 should be carefully evaluated in future studies, particularly when (2)-adrenergic blockers are used in patients with triple negative breast cancer.